Skip to content
HowShorted

SELLAS Life Sciences Group, Inc. short interest in 2022

In 2022, SELLAS Life Sciences Group, Inc.'s disclosed short interest ran from 5.38% of shares outstanding on 14 Jan 2022 to 6.01% on 30 Dec 2022, a change of +0.63 percentage points. The year's high was 6.31% on 31 Mar 2022 and its low 4.00% on 14 Oct 2022, averaging 5.41% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 12.69 days on 28 Feb 2022. Full history: SELLAS Life Sciences Group, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for SELLAS Life Sciences Group, Inc. in 2022

2022 in figures

Start of year
5.38% (14 Jan 2022)
End of year
6.01% (30 Dec 2022)
Change
+0.63 pp
High
6.31% (31 Mar 2022)
Low
4.00% (14 Oct 2022)
Average
5.41%
Highest days to cover
12.69 (28 Feb 2022)
SEC filings marked
7

Every report in 2022

SELLAS Life Sciences Group, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20225.38%8.09
31 Jan 20226.21%4.15
15 Feb 20226.29%8.58
28 Feb 20226.22%12.69
15 Mar 20226.30%10.52
31 Mar 20226.31%7.3810-K filed
14 Apr 20225.76%1.01
29 Apr 20225.46%4.24
13 May 20225.93%5.4710-Q filed, results (8-K)
31 May 20225.33%3.41
15 Jun 20225.64%5.38
30 Jun 20225.63%6.07
15 Jul 20225.40%9.42
29 Jul 20225.27%10.07
15 Aug 20224.32%5.3210-Q filed, results (8-K)
31 Aug 20224.06%9.45
15 Sep 20224.06%12.68
30 Sep 20224.04%7.07
14 Oct 20224.00%11.21
31 Oct 20224.85%1.26
15 Nov 20225.61%1.4210-Q filed, results (8-K)
30 Nov 20225.90%4.63
15 Dec 20225.96%9.36
30 Dec 20226.01%10.56

See also: SELLAS Life Sciences Group, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.